Loading...

Quest Diagnostics Incorporated

DGXNYSE
HealthcareMedical - Diagnostics & Research
$174.32
$0.67(0.39%)

Quest Diagnostics Incorporated (DGX) Stock Overview

Explore Quest Diagnostics Incorporated’s financial performance, market position, analyst ratings, and future outlook.

Revenue Growth
6.70%
6.70%
Profit Growth
$8.08
1.99%
EPS Growth
$8.08
2.77%
Operating Margin
13.85%
6.66%
ROE
13.22%
1.99%
Dividend Yield
0.00%
6.36%

Analyst Recommendations

Strong Buy
0
Buy
1
Hold
3
Sell
0
Strong Sell
0

Price Targets

Low$154.00
Average$173.92
High$195.00

Company Profile

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

CEO

Mr. James E. Davis

Employees

55,000

Headquarters

500 Plaza Drive, Secaucus, NJ

Founded

1996

Frequently Asked Questions